NeoGenomics Laboratories, Inc. is a publicly traded high-complexity national clinical laboratory company that specializes in cancer diagnostic testing, focused on molecular and genomic approaches. NeoGenomics has been associated with innovation in providing world-class pathology and cancer genetic diagnostic services for pathologists, oncologists, urologists and gastroenterologists, as well as hospitals throughout the USA. The company mission also includes the integration of technical advances in molecular methodologies including computer-aided pattern-recognition mathematical algorithms in order to integrate data from multiple analytes and thereby develop precise (personalized) predictive tools for the diagnosis of disease, prognosis and response to therapy. The company has a unique business model in that it is committed to partnering with routine diagnostic laboratories, thereby providing them with the option of technical-component-only testing for esoteric biomarkers and allowing local control of the professional component, in the interpretation and the review of raw data. The company, through innovative research and development, is dedicated to the cost-effective delivery of leading-edge, high-quality patient care through the application of precise and personalized laboratory medicine.